Detalhe da pesquisa
1.
Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Osteoporos Int
; 33(6): 1243-1256, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35165774
2.
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
Diabetes Obes Metab
; 20(1): 121-128, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28661585
3.
Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.
Bone
; 154: 116209, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34547521
4.
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
J Bone Miner Res
; 37(2): 256-264, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34738660
5.
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
J Bone Miner Res
; 35(7): 1333-1342, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445228
6.
Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Diabetes Technol Ther
; 19(9): 516-526, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28722480
7.
Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.
Postgrad Med
; 128(8): 731-739, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27690710
8.
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Diabetes Care
; 38(12): 2217-25, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26084341